StockNews.com Upgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) to Hold
StockNews.com Upgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) to Hold
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) was upgraded by research analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued on Thursday.
在周四发布的一份研究报告中，斯托克新闻网的研究分析师将Licion PharmPharmticals(纳斯达克代码：LXRX-GET)的评级从卖出上调为持有。
Lexicon Pharmaceuticals Stock Performance
Licion制药股表现
Shares of Lexicon Pharmaceuticals stock opened at $2.08 on Thursday. The business's fifty day simple moving average is $2.14 and its 200 day simple moving average is $2.37. The firm has a market capitalization of $392.55 million, a P/E ratio of -3.35 and a beta of 1.34. Lexicon Pharmaceuticals has a 12 month low of $1.31 and a 12 month high of $4.72. The company has a current ratio of 7.54, a quick ratio of 7.54 and a debt-to-equity ratio of 0.17.
Licion PharmPharmticals的股票周四开盘报2.08美元。该业务的50日简单移动均线切入位为2.14美元，200日简单移动均线切入位为2.37美元。该公司的市值为3.9255亿美元，市盈率为-3.35，贝塔系数为1.34。Licion PharmPharmticals的12个月低点为1.31美元，12个月高位为4.72美元。该公司的流动比率为7.54，速动比率为7.54，债务权益比率为0.17。
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) last issued its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. The business had revenue of $0.04 million for the quarter. Lexicon Pharmaceuticals had a negative return on equity of 92.19% and a negative net margin of 77,648.80%. As a group, analysts anticipate that Lexicon Pharmaceuticals will post -0.6 EPS for the current year.
Licion PharmPharmticals(纳斯达克代码：LXRX-GET Rating)最近一次发布季度收益报告是在11月9日星期三。这家生物制药公司公布了该季度每股收益(0.13美元)，比分析师普遍预测的(0.15美元)高出0.02美元。该业务本季度的收入为40万美元。Licion制药公司的净资产回报率为负92.19%，净利润率为负77648.80%。分析师预计，作为一个整体，Licion制药公司本年度的每股收益将为-0.6%。
Institutional Trading of Lexicon Pharmaceuticals
Licion制药的机构性交易
About Lexicon Pharmaceuticals
关于Licion制药公司
(Get Rating)
(获取评级)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.
Licion制药公司是一家生物制药公司，专注于药品的发现、开发和商业化。该公司正在开发的口服小分子药物候选药物包括用于治疗心力衰竭和1型糖尿病的已完成第三阶段临床试验的索他利氟秦；以及用于治疗神经病理性疼痛的LX9211。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Lexicon Pharmaceuticals (LXRX)
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- 免费获取StockNews.com关于Licion PharmPharmticals(LXRX)的研究报告
- 哪两家蓝筹科技公司提高了他们的指引？
- 你应该担心埃隆·马斯克出售他持有的特斯拉股票吗？
- 拖拉机库存能否突破杯柄收购点？
- 现在不是购买Lennar的时候，但时机即将到来
- 马伦汽车公司改变游戏规则的消息
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Licion PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Licion制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。